DR info

Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111

Drugs and their primary sponsors and trial info

1) Inosine 5'-monophosphate
   Yonsei University
      2018   Phase 2   NCT03403309   Korea, Republic of;
AAV2-GDNF gene therapy
   Brain Neurotherapy Bio, Inc.
      2022   Phase 1   NCT04680065   United States;
AFFITOPE® PD01A + Adjuvant
   Affiris AG
      2014   Phase 1   NCT02270489   France;
AFFITOPE® PD03A + Adjuvant
   Affiris AG
      2014   Phase 1   NCT02270489   France;
ATH434 dose level 1
   Alterity Therapeutics
      2022   Phase 2   NCT05109091   -
ATH434 dose level 2
   Alterity Therapeutics
      2022   Phase 2   NCT05109091   -
AZD3241
   AstraZeneca
      2015   Phase 2   NCT02388295   Austria;Finland;France;Italy;Sweden;United Kingdom;United States;
   AstraZeneca AB
      2015   Phase 2   EUCTR2014-004902-13-SE   Austria;Finland;France;Italy;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-004902-13-GB   Finland;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-004902-13-FI   Austria;Finland;France;Italy;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-018157-23-GB   Austria;Spain;United Kingdom;
      2010   -   EUCTR2009-018157-23-ES   Austria;Spain;United Kingdom;
      2010   -   EUCTR2009-018157-23-AT   Austria;Spain;United Kingdom;
AZILECT 1 mg comprimidos
   Teva Pharmaceutical Industries Ltd
      2009   Phase 2   EUCTR2009-014644-11-ES   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
Abdominal compression
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States;
Accelerometer
   Vanderbilt University Medical Center
      2021   -   NCT04782830   United States;
Adjuvant without active component
   Affiris AG
      2014   Phase 1   NCT02270489   France;
Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation
   Indonesia University
      2020   -   NCT04876326   Indonesia;
Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation
   Indonesia University
      2020   -   NCT04876326   Indonesia;
Ampreloxetine
   THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
      2019   Phase 3   EUCTR2018-003289-15-IT   Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003289-15-DE   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-HU   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-ES   Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampreloxetine chydrochloride
   Theravance Biopharma Ireland Limited
      2019   Phase 3   EUCTR2018-003289-15-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ampreloxetine hydrochloride
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003941-41-PT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003941-41-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003289-15-PT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-IT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-HU   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-ES   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-EE   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-EE   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-DK   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Angiotensin-(1-7)
   Vanderbilt University Medical Center
      2016   Early Phase 1   NCT02591173   United States;
Anti-Parkinson medication
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Atomexetine
   NYU Langone Health
      2016   Phase 2   NCT02796209   United States;
Autologous Adipose Mesenchymal Stem Cell Implantation
   Indonesia University
      2020   -   NCT04876326   Indonesia;
Autologous Mesenchymal Stem Cells
   Mayo Clinic
      2021   Phase 2   NCT05167721   United States;
      2012   Phase 1/Phase 2   NCT02315027   United States;
Autologous mesenchymal stem cells
   Yonsei University
      2008   Phase 2   NCT00911365   Korea, Republic of;
Automated abdominal binder
   Vanderbilt University Medical Center
      2018   Phase 1/Phase 2   NCT03482297   United States;
BHV-3241
   Biohaven Pharmaceuticals, Inc
      2020   Phase 3   EUCTR2019-001100-38-DE   Austria;China;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001100-38-GB   Austria;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001100-38-FR   Austria;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001100-38-AT   Austria;China;France;Germany;Italy;United Kingdom;United States;
   Biohaven Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001100-38-IT   Austria;China;France;Germany;Italy;United Kingdom;United States;
BHV-4157
   University of California, Los Angeles
      2017   Phase 3   NCT03408080   United States;
BIIB101
   Biogen
      2020   Phase 1   NCT04165486   Austria;France;Germany;Portugal;United Kingdom;
Blood sampling
   University Hospital, Bordeaux
      2020   -   NCT04250493   France;
Brain Magnetic Resonance Imaging (MRI)
   University Hospital, Bordeaux
      2020   -   NCT04250493   France;
Bydureon
   University College London (UCL)
      2020   Phase 2   EUCTR2020-000122-26-GB   United Kingdom;
CS10BR05
   Corestem, Inc.
      2018   Phase 1   NCT03265444   Korea, Republic of;
Captopril
   Vanderbilt University
      2011   Phase 1   NCT01292694   United States;
Carbidopa
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States;
Carbidopa 200mg oral dose
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States;
DaTSCAN™ Ioflupane (123I) Injection
   GE Healthcare
      2020   Phase 3   NCT04193527   China;
Deep Brain Stimulation
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States;
Determination of objective and subjective pain threshold
   University Hospital, Toulouse
      2011   -   NCT01577992   France;
Domperidone
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia;
Droxidopa
   Chelsea Therapeutics
      2008   Phase 3   NCT00738062   Australia;Canada;New Zealand;United States;
   Loma Linda University
      2021   Phase 2   NCT03446807   United States;
   Mount Sinai School of Medicine
      1999   -   NCT00004478   United States;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States;
   Vanderbilt University Medical Center
      2016   Phase 1   NCT02897063   United States;
EGCG as putative neuroprotective agent
   Dr. Johannes Levin
      2014   Phase 3   NCT02008721   Germany;
Emeramide
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
Entacapone
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States;
Entacapone 400mg oral dose
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States;
Exenatide
   University College London (UCL)
      2020   Phase 2   EUCTR2020-000122-26-GB   United Kingdom;
Exenatide Pen Injector [Bydureon]
   University College, London
      2020   Phase 2   NCT04431713   United Kingdom;
Fipamezole
   Juvantia Pharma Ltd
      2008   Phase 2   NCT00758849   France;Portugal;
Fipamezole hydrochloride 30 mg oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
Fipamezole hydrochloride 60 mg oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
Fipamezole hydrochloride 90 mg oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
Fludrocortisone
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia;
Flumazenil
   Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      2013   -   JPRN-UMIN000011111   Japan;
Fluoxétine
   University Hospital, Bordeaux
      2010   -   NCT01136213   France;
Flutemetamol F18
   Skane University Hospital
      2017   -   NCT03174938   Sweden;
Gold
   Navy general hospital
      2015   Phase 0   ChiCTR-DPC-15005941   China;
   West China Hospital of Sichuan University
      2020   Phase 0   ChiCTR2000033282   China;
Homeostasis Model Assessment of insulin resistance (HOMA)
   University Hospital, Bordeaux
      2020   -   NCT04250493   France;
Hydrogen
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one
   AstraZeneca AB
      2015   Phase 2   EUCTR2014-004902-13-SE   Austria;Finland;France;Italy;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-004902-13-GB   Finland;Sweden;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-004902-13-FI   Austria;Finland;France;Italy;Sweden;United Kingdom;United States;
Intranasal Insulin
   Peter Novak
      2014   Phase 2   NCT02064166   United States;
Intravenous immunoglobulin (IVIg)
   University of Massachusetts, Worcester
      2008   Phase 2   NCT00750867   United States;
Intravesical injection of Botulinum A toxin
   University Of Perugia
      2008   Phase 4   NCT00822913   -
JP-1730/F01
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
JP-1730/F02
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
JP-1730/F03
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal;
      2008   -   EUCTR2007-004890-24-FR   France;Portugal;
L-Threo DOPS
   University Hospital, Toulouse
      2014   Phase 2/Phase 3   NCT02071459   France;
LITIO CARBONATO
   UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
      2009   -   EUCTR2009-016377-15-IT   Italy;
Levodopa
   University Hospital, Toulouse
      2002   -   NCT01044992   France;
Levodopa test
   University Hospital, Toulouse
      2011   -   NCT01577992   France;
Losartan
   Vanderbilt University
      2011   Phase 1   NCT01292694   United States;
Lu AF82422
   H. Lundbeck A/S
      2021   Phase 2   NCT05104476   Japan;United States;
Metoprolol tartrate
   Vanderbilt University
      2010   -   NCT01044693   United States;
Midodrine
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States;
      2018   Phase 1/Phase 2   NCT03482297   United States;
      2016   Phase 1   NCT02897063   United States;
      2015   Phase 1   NCT02429557   United States;
Midodrine or atomoxetine pill
   Vanderbilt University Medical Center
      2021   -   NCT04782830   United States;
Modal
   Oregon Health and Science University
      2021   -   NCT04468919   United States;
N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
NBMI
   EmeraMed
      2019   Phase 2   NCT04184063   Slovenia;
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia;
NT 101
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;
Nebivolol
   Vanderbilt University
      2010   -   NCT01044693   United States;
Nitrogen
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
Normal saline
   Yonsei University
      2008   Phase 2   NCT00911365   Korea, Republic of;
PROZAC
   CHU Toulouse
      2008   -   EUCTR2007-004922-26-FR   France;
Pseudoephedrine
   Vanderbilt University
      2003   Phase 1   NCT00179023   United States;
Pseudoephedrine + 480 ml water
   Vanderbilt University
      2014   Early Phase 1   NCT02149901   United States;
Pseudoephedrine + 50 ml water
   Vanderbilt University
      2014   Early Phase 1   NCT02149901   United States;
RASAGILINA MESILATO
   Teva Pharmaceutical Industries Ltd
      2009   Phase 2   EUCTR2009-014644-11-ES   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
Raclopride
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan;
Rasagiline
   Teva Pharmaceutical Industries Ltd
      2009   -   EUCTR2009-014644-11-IT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
Rasagiline mesylate
   Teva Pharmaceutical Industries
      2009   Phase 2   NCT00977665   Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
   Teva Pharmaceutical Industries Ltd
      2010   Phase 2   EUCTR2009-014644-11-GB   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-014644-11-PT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-014644-11-NL   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-014644-11-AT   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   Phase 2   EUCTR2009-014644-11-FR   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-014644-11-HU   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2009-014644-11-DE   Austria;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
Rifampicin
   Phillip Low
      2011   Phase 3   NCT01287221   United States;
Riluzole
   King's College London
      2000   Phase 3   NCT00211224   United Kingdom;
Rituximab
   First Affiliated Hospital of Fujian Medical University
      2019   Phase 2   NCT04004819   China;
SAFINAMIDE METANSOLFONATO
   ZAMBON SPA
      2019   Phase 2   EUCTR2018-004145-16-IT   Italy;Spain;
Safinamide Methanesulfonate
   Zambon SpA
      2019   Phase 2   NCT03753763   Italy;Spain;
Safinamide methanesulfonate
   Zambon SpA
      2019   Phase 2   EUCTR2018-004145-16-ES   Spain;
Saline
   Vanderbilt University
      2010   Phase 1   NCT01119417   United States;
   Vanderbilt University Medical Center
      2016   Early Phase 1   NCT02591173   United States;
Sham binder
   Vanderbilt University Medical Center
      2018   Phase 1/Phase 2   NCT03482297   United States;
Sham compression
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States;
Sildenafil
   Vanderbilt University
      2010   -   NCT01044693   United States;
Sirolimus
   NYU Langone Health
      2018   Phase 2   NCT03589976   United States;
Sunphenon EGCg
   Hospital of the Ludwig-Maximilians-University of Munich
      2013   Phase 3   EUCTR2012-000928-18-DE   Germany;
TD-9855
   THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
      2019   Phase 3   EUCTR2018-003289-15-IT   Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Theravance Biopharma
      2016   Phase 2   NCT02705755   United States;
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003941-41-PT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003941-41-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003289-15-PT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003289-15-DE   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-IT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-HU   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-ES   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-EE   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003941-41-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-HU   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-ES   Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-EE   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-DK   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003289-15-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Tllsh2910
   National Taiwan University Hospital
      2019   Phase 3   NCT03901638   Taiwan;
Tolterodine
   Xuanwu Hospital, Capital Medical University
      2021   -   ChiCTR2100046394   China;
Trimethaphan
   Vanderbilt University
      2016   Phase 1   NCT02726711   United States;
      2003   Phase 1   NCT00179023   United States;
Ubiquinol
   Department of Neurology, the University of Tokyo Hospital
      2013   -   JPRN-UMIN000010712   Japan;
Verdiperstat
   Biohaven Pharmaceuticals, Inc
      2020   Phase 3   EUCTR2019-001100-38-DE   Austria;China;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001100-38-GB   Austria;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001100-38-FR   Austria;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001100-38-AT   Austria;China;France;Germany;Italy;United Kingdom;United States;
   Biohaven Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001100-38-IT   Austria;China;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 3   NCT03952806   Austria;France;Germany;Italy;United Kingdom;United States;
   Brigham and Women's Hospital
      2020   Early Phase 1   NCT04616456   United States;
Water
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan;
Xadago
   ZAMBON SPA
      2019   Phase 2   EUCTR2018-004145-16-IT   Italy;Spain;
   Zambon SpA
      2019   Phase 2   EUCTR2018-004145-16-ES   Spain;
Xeomin
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States;
Z7219
   ZAMBON SPA
      2019   Phase 2   EUCTR2018-004145-16-IT   Italy;Spain;
Zoledronic Acid 5Mg/Bag 100Ml Inj
   California Pacific Medical Center Research Institute
      2019   Phase 4   NCT03924414   United States;
[18F]FDOPA
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States;
[F-18]PBR06
   Brigham and Women's Hospital
      2020   Early Phase 1   NCT04616456   United States;